Stockholm - Delayed Quote SEK

SciBase Holding AB (publ) (SCIB.ST)

0.4250

+0.0350

+(8.97%)

At close: 3:42:00 PM GMT+2

SciBase continues US expansion, on-boards Several US Dermatology Practices that Specialize in Skin Cancer Detection

SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that it has on-boarded several US dermatology practices that specialize in skin cancer detection, diagnosis and treatment. Through these US practices, SciBase will further their mission to improve outcomes for patients and clinicians by expanding access of the Nevisense test to additional states in the US.

PR Newswire 3 months ago

SCIB.ST
+8.97%
New review article highlights Nevisense effectiveness in identifying malignant skin lesions

SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that a new review article has been published highlighting the performance of Nevisense in identifying malignant skin lesions. The article titled "Progressive approaches in oncological diagnosis and surveillance: real-time impedance-based techniques and advanced algorithms" was written by researchers at George Washington University, Washington DC, USA, and h

PR Newswire 3 months ago

SCIB.ST
+8.97%
Nevisense (EIS) included in updated German (S1) imaging guidelines

SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that updated German guidelines for imaging (S1) has been published today. Nevisense (EIS - or "MIS - Mikroelektrische Impendanzspektroskopie") is mentioned as a technology for detecting Melanoma and Non-Melanoma skin cancer as well as the future potential in Atopic Dermatitis (AD). The guidelines conclude that "If seborrhoeic keratoses and inflammatory lesi

PR Newswire 3 months ago

5J3.F

SCIB.ST
+8.97%
SciBase initiates sales collaboration in Italy

SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announces today the collaboration with Kilabs srl, an Italian Company with expertise in dermatology, which now will be able to offer access to better diagnostics of skin cancer in Italy.

PR Newswire 6 months ago

SCIB.ST
+8.97%
SciBase continues US expansion and will attend Fall Clinical conference

SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders will attend a leading US dermatology conference, Fall Clinical, to further enhance the clinical adoption and market expansion of Nevisense. The Fall Clinical conference attracts more than 1,100 clinicians looking to bridge gaps within the detection and diagnosis of melanoma clinical pathway. The conference offers comprehensive workshops and sessions led by top dermatology

PR Newswire 6 months ago

SCIB.ST
+8.97%
SciBase partner with a large health care group in Los Angeles, Unified Health, and receives a first order

SciBase Holding AB ("SciBase") (STO: SCIB), SciBase, a leading developer of augmented intelligence-based solutions for skin disorders announced today that it continues to expand in California with a collaboration agreement with Unified Health. Unified Health has nine clinics in Southern California.

PR Newswire 10 months ago

SCIB.ST
+8.97%
SciBase welcomes new chairman and thanks the former

SciBase Holding AB ("SciBase") (STO: SCIB), SciBase, a leading developer of AI-based solutions for skin diseases, today announces the election of Jesper Høiland as the new Chairman of the Board.

PR Newswire 10 months ago

SCIB.ST
+8.97%
New German study shows Nevisense significantly improves dermatologists clinical decisions

SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that a new clinical study has been published presenting the improvement that the Nevisense provides over visual and dermoscopic evaluation when clinical evaluations were done by German dermatologists. The article named "Utilizing Data from Electrical Impedance Spectroscopy Significantly Improves the Decision to Biopsy Pigmented Skin Lesions Beyond Clinical

PR Newswire 11 months ago

SCIB.ST
+8.97%

Performance Overview

Return	SCIB.ST	OMX Stockholm 30 Index (^OMX)
YTD	+3.66%	+2.65%
1-Year	+55.11%	-2.05%
3-Year	-90.13%	+27.93%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

SciBase Holding AB (publ) (SCIB.ST)

SciBase continues US expansion, on-boards Several US Dermatology Practices that Specialize in Skin Cancer Detection

New review article highlights Nevisense effectiveness in identifying malignant skin lesions

Nevisense (EIS) included in updated German (S1) imaging guidelines

SciBase initiates sales collaboration in Italy

SciBase continues US expansion and will attend Fall Clinical conference

SciBase partner with a large health care group in Los Angeles, Unified Health, and receives a first order

SciBase welcomes new chairman and thanks the former

New German study shows Nevisense significantly improves dermatologists clinical decisions

Performance Overview